As per MRFR analysis, the China High Throughput Screening Market Size was estimated at 1.19 (USD Billion) in 2024. The China High Throughput Screening Market Industry is expected to grow from 1.3 (USD Billion) in 2025 to 5.04 (USD Billion) by 2035.
The China High Throughput Screening Market CAGR (growth rate) is expected to be around 13.096% during the forecast period (2025 - 2035).
In China, the High Throughput Screening (HTS) market is witnessing significant growth fueled by various factors, notably the increasing investments in drug discovery and development. The Chinese government prioritizes biotechnology, evidenced by initiatives such as the "Made in China 2025" strategy, which emphasizes innovation in life sciences.
This governmental focus is a key market driver, encouraging both domestic and international pharmaceutical companies to adopt HTS technologies for efficient and rapid screening of compounds. Moreover, as the demand for personalized medicine rises, there is an opportunity for the HTS market to evolve, particularly in enabling tailored drug therapies based on individual genetic profiles.
This trend aligns with the broader healthcare reforms in China aimed at enhancing patient care and treatment outcomes. Additionally, advancements in automation and data analysis are transforming HTS processes, making it more accessible for research institutions and smaller biotech firms in China to participate in the market.
Recent trends also indicate a growing collaboration among universities, research centers, and pharmaceutical companies to develop innovative HTS solutions, enhancing the overall research capacity. Furthermore, with the increasing adoption of artificial intelligence in various sectors, there is potential for AI-driven HTS solutions to emerge, streamlining the drug discovery process and increasing accuracy.
Overall, the evolving landscape of the High Throughput Screening market in China demonstrates a promising environment for innovation and growth, with opportunities for participants to address emerging healthcare needs effectively.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The demand for high throughput screening in China is primarily driven by the increasing need for rapid and efficient drug development processes. According to the National Health Commission of the People's Republic of China, there has been a notable increase in drug approvals.
A reported average of approximately 16.8% annual growth in approved new drugs occurred between 2015 and 2020. This surge necessitates innovative screening methods to identify potential drug candidates quickly.
China National Pharmaceutical Group Corporation and other well-established companies are actively engaging in the promotion of new screening technologies, which improves the productivity of research and development in therapeutics and aids in the growth of the China High Throughput Screening Market Industry.
China is witnessing a significant rise in chronic disease incidences, such as cancer and diabetes, which directly influences the demand for high throughput screening technologies. For instance, data from the National Cancer Center of China indicates that there was a staggering increase of about 18% in cancer cases from 2015 to 2020.
This has led to a greater emphasis on early detection and targeted therapies. As healthcare systems adapt to manage these diseases, organizations including Novartis China are increasingly utilizing high throughput screening techniques to identify and develop effective treatments, further propelling the growth of the China High Throughput Screening Market.
Recent advancements in biotechnology have significantly contributed to the growth of the China High Throughput Screening Market Industry. The Chinese government has implemented various policies to foster innovation in biopharmaceuticals, with investments in biotechnology exceeding USD 40 billion in the past five years, according to the Ministry of Science and Technology.
Such advancements have facilitated the integration of high throughput screening technologies with genomic and proteomic research, maximizing the potential of drug discovery processes. Companies like WuXi AppTec have emerged as leaders in this space by leveraging cutting-edge technologies, further driving market growth.
Investment in Research and Development (R&D) activities is a pivotal driver for the China High Throughput Screening Market. The Chinese government has declared its dedication to improving healthcare capabilities, with R&D funding in the pharmaceutical sector rising consistently by an average of 12% each year since 2016.
This is backed by initiatives like the 'Made in China 2025' policy, which emphasizes high-tech manufacturing and innovation. The investment from both private and public sectors is helping organizations such as Sinopharm Group to enhance their screening technologies, thereby significantly contributing to the growth of screening methodologies in the country.
The Product and Service segment within the China High Throughput Screening Market is characterized by a diverse range of components that play a crucial role in the efficiency and effectiveness of screening processes across various biotechnology and pharmaceutical industries. Reagents are key elements, often comprising specialized proteins and chemicals that facilitate the analysis of biological processes, making them fundamental to achieving accurate and reliable results.
Assay kits, which combine various reagents and protocols, streamline the screening procedures and are widely adopted in laboratory settings for their ease of use and consistent performance. Instruments equipped for high throughput screening are vital as they automate the screening process, allowing for the rapid testing of thousands of samples simultaneously, which is essential for research in drug discovery and genomics.
Consumables, such as microplates and pipette tips, support laboratory functioning and must be of high quality to maintain the integrity of the screening results. Accessories provide essential support to the main instruments and reagents, ensuring that the high throughput screening systems operate smoothly and effectively.
Software solutions are becoming increasingly important in managing and analyzing screening data, with advanced algorithms helping scientists make sense of large datasets and derive meaningful insights in a fraction of the time it would traditionally take. Additionally, services associated with high throughput screening, including maintenance and support, are crucial for ensuring that systems remain operational and up to date, thus minimizing downtime and enhancing productivity.
As the China High Throughput Screening Market continues to evolve, these various elements are increasingly interconnected, reflecting trends toward greater integration and automation in laboratory processes. The growing demand for personalized medicine and advancements in biotechnology are expected to bolster the importance of these products and services, further driving the market's progress.
Overall, each part of the Product and Service segment contributes significantly to the overall efficiency, reliability, and effectiveness of screening practices in China’s regenerative medicine, pharmaceutical development, and diagnostic sectors.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China High Throughput Screening Market within the Technology segment is experiencing substantial growth, driven by advancements in drug discovery and Research and Development initiatives. Among various methodologies, Cell-Based Assays are fundamentally important as they facilitate the evaluation of biochemical and cellular activity, playing a key role in the development of therapeutics.
Both 2D Cell Culture and 3D Cell Culture techniques are increasingly relevant, as the latter offers a more physiologically relevant model that closely mimics in vivo conditions, thus enhancing the accuracy of screening results.
Scaffold-Based Technologies and Scaffold-free Technologies are noteworthy for their applications in specific assays, particularly in regenerative medicine and tissue engineering. The continued evolution of Hanging-drop Plates and Ultra-low Binding Plates is pivotal, as they provide improved conditions for cell growth and assay performance, minimizing sample loss and contamination, which are significant challenges in high throughput screening processes.
Overall, the diverse range of methodologies under the Technology segment is crucial in propelling the China High Throughput Screening Market forward, with each approach addressing unique challenges in drug discovery and delivering relevant insights into the pharmaceutical landscape.
The China High Throughput Screening Market is gaining significant traction as advancements in technology and increased investment in drug discovery processes shape the competitive landscape. This market is characterized by a diverse pool of players encompassing both established companies and emerging start-ups, each aiming to enhance the efficiency and effectiveness of screening methods used in biological and chemical research.
The competitive insights indicate that companies are continually innovating to deliver cutting-edge solutions that accommodate the unique challenges of the Chinese market, such as regulatory constraints and the growing demand for personalized medicine. With China positioning itself as a global hub for pharmaceutical research and development, the high throughput screening segment is witnessing intense competition.
This drives players to differentiate themselves through product offerings, technological advancements, and strategic partnerships. Wuxi AppTec has solidified its position in the China High Throughput Screening Market through its comprehensive suite of services, which are essential for accelerating drug discovery processes.
The company’s strengths lie in its robust research capabilities that leverage advanced technology platforms, allowing for rapid and accurate screening. Wuxi AppTec boasts an extensive network of clients within the pharmaceutical and biotechnology sectors, which enhances its market presence significantly.
With a commitment to quality and innovation, the company has become a preferred partner for many organizations looking to streamline their screening processes. Its ability to integrate various services, from compound library design to lead optimization, adds to the appeal for domestic and international clients seeking tailored solutions in the competitive landscape of high throughput screening.
Tecan Group has also made profound inroads in the China High Throughput Screening Market, driven by its strong portfolio of automated laboratory instruments and high-quality consumables. The company's key products include liquid handling systems and workflow solutions that enhance the efficiency and throughput of screening processes, catering specifically to the needs of academic and industrial laboratories across China.
Tecan has established a notable market presence characterized by strategic collaborations and partnerships that bolster its operational capabilities. Strengthened by a series of cultivation in customer relationships and innovative product offerings, Tecan has positioned itself as a reliable partner in the region’s drug discovery efforts.
Furthermore, the company actively pursues mergers and acquisitions to fortify its market standing and expand its technological edge, continuously refining its offerings to meet the evolving demands of high throughput screening in China.
Recent developments in the China High Throughput Screening Market indicate a robust growth trajectory fueled by advancements in Research and Development and the increasing demand for efficient drug discovery technologies. Companies such as Wuxi AppTec and Shanghai ChemPartner are significantly contributing to the market's expansion by enhancing their service offerings.
Tecan Group and PerkinElmer continue to innovate their technology platforms, allowing for more streamlined and reliable screening processes. In terms of mergers and acquisitions, Corning Incorporated recently acquired a strategic asset in September 2023 to bolster its position in the biotechnology sector, further reinforcing its capabilities in high throughput screening.
Noteworthy is the ongoing collaboration efforts between Hitachi HighTech and Agenus aimed at integrating cutting-edge screening technologies to enhance research in immunotherapy modalities. The market is experiencing heightened valuation growth, driven by increased investments in biopharmaceutical sectors and technological advancements by companies like Thermo Fisher Scientific and Agilent Technologies.
In the last two years, significant shifts have occurred within the China High Throughput Screening Market, including increased regulatory support for biotechnology innovation, emphasizing the government's commitment to advancing healthcare technology.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.19(USD Billion) |
| MARKET SIZE 2024 | 1.3(USD Billion) |
| MARKET SIZE 2035 | 5.04(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.096% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Wuxi AppTec, Tecan Group, Acea Biosciences, Shanghai ChemPartner, Corning Incorporated, Molecular Devices, Promega Corporation, Hitachi HighTech, BioRad Laboratories, Sartorius AG, PerkinElmer, Agilent Technologies, GE Healthcare, Agenus, Thermo Fisher Scientific |
| SEGMENTS COVERED | Product & Service, Technology |
| KEY MARKET OPPORTUNITIES | Increased R&D investment, Growing biopharma sector, Rising demand for precision medicine, Expansion of drug discovery initiatives, Advancements in automation technology |
| KEY MARKET DYNAMICS | Increased drug discovery activities, Rising demand for personalized medicine, Advancements in automation technology, Growing investments in biotechnology, Expanding applications in genomics research |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The China High Throughput Screening Market is expected to be valued at 1.3 billion USD in 2024.
By 2035, the market is projected to reach a value of 5.04 billion USD.
The market is expected to grow at a CAGR of 13.096% from 2025 to 2035.
Key players include Wuxi AppTec, Tecan Group, Acea Biosciences, and Thermo Fisher Scientific.
The market for reagents is valued at 0.45 billion USD in 2024 and is expected to reach 1.74 billion USD by 2035.
Assay kits instruments are valued at 0.3 billion USD in 2024 and projected to rise to 1.21 billion USD in 2035.
The consumables segment is expected to reach a value of 1.0 billion USD by 2035.
The accessories segment is valued at 0.15 billion USD in 2024 and forecasted to grow to 0.6 billion USD by 2035.
The software segment is anticipated to reach a market value of 0.49 billion USD by 2035.
Key growth drivers include rising demand for drug discovery and advancements in biotechnology.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
